
Ultra-high purity BIP® cylinders aim to give analytical laboratories cleaner baselines and lower detection limits
Is FDA getting tired of writing warning letters? A new draft guidance shows how companies should respond to Form 483 observations.
In March, the Agency published a draft guidance on Responding to FDA Form 483 Observations.1 We will discuss it from a laboratory perspective, covering:





